Prof Matteo Lambertini and Prof Virginia Kaklamani talk to ecancer in this expert panel discussion from the San Antonio Breast Cancer Symposium 2024, exploring groundbreaking advancements in genomic testing, and their impact on breast cancer treatment.

Key topics include findings from the TAILORx and ADAPT trials, the role of recurrence scores in guiding chemotherapy choices and testing around pregnancy.

The discussion highlights the use of genomic risk assessment to personalise treatment, the evolving role of anthracyclines, and the potential of CDK4/6 inhibitors to reduce chemotherapy reliance, offering invaluable insights for clinicians and researchers alike.